Randomized, prospective, and double-blind trial of new beta-lactams in the treatment of appendicitis.
A prospective, randomized, and double-blind study was conducted with 864 patients operated on for appendicitis. In early cases, including normal and acute appendicitis, one dose of antibiotic was given. The rate of postappendectomy septic complications in patients who received cefotaxime, cefoperazone, or moxalactam was very low (about 3%), and there was no statistical difference between the drugs. For late cases, including gangrenous and perforated appendicitis, the antibiotics were continued for 5 days. Moxalactam decreased significantly the septic complications in these patients when compared with the other two drugs. It is safe, free from serious toxic side effects, and more convenient and easier to administer than combination antibiotic therapy. The main disadvantage of moxalactam is its high cost, but this has to be balanced against the savings in nursing time, the cost of monitoring renal function and serum level when aminoglycosides are used, and the reduced usage and manipulation of infusion sets.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001062:Appendectomy; D002438:Cefoperazone / Q000627:therapeutic use; D002439:Cefotaxime / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007700:Kinetics; D009070:Moxalactam / Q000627:therapeutic use; D011292:Premedication; D011446:Prospective Studies; D011897:Random Allocation; D013530:Surgical Wound Infection / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D002438:Cefoperazone; D002439:Cefotaxime; D009070:Moxalactam